Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 286 AL 300

Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events

Porsteinsson AP, Chumki SR, Wang D, Such P, Palma AM, Zhang Z, Shah A, Kalu U, Montano CB.

Drug Saf. 2026 Aug;49(8):969-983. doi: 10.1007/s40264-026-01670-w. Epub 2026 Apr 10.

Sleep abnormalities across different clinical stages of Alzheimer's disease: A systematic review and network meta-analysis

Zhang Y, Ren R, Feng X, Wang M, Huang J, Shi J, Lu L, Sanford LD, Vitiello MV, Tang X.

Sleep Med Rev. 2026 Aug;88:102289. doi: 10.1016/j.smrv.2026.102289. Epub 2026 Apr 9.

Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort

Exalto LG, Syaziyah SS, Fang XT, Prins ND, Sikkes SAM, van der Flier WM, Vijverberg EGB, Lim YMF.

J Prev Alzheimers Dis. 2026 Aug;13(7):100580. doi: 10.1016/j.tjpad.2026.100580. Epub 2026 May 7.

Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementias

EADB; EADI; Bonn; ADGC; CHARGE; FinnGen; GERAD; GR@ACE/DEGESCO; PGC-ALZ.

Nat Genet. 2026 Jun;58(6):1214-1225. doi: 10.1038/s41588-026-02583-1. Epub 2026 Jun 3.

Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review

Deng R, Shargorodsky A, Teopiz K, Dri CE, Wong S, Le GH, Zheng YJ, McIntyre RS.

CNS Spectr. 2026 Jun 9;31(1):e18. doi: 10.1017/S1092852926100996.

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression

da Silva AMP, Tudella GCN, Gonçalves OR, Ribeiro FV, Pereira MAOM, do Nascimento MDVS, Nogueira BV, Santos DH, de Gobbi Porto FH, Høilund-Carlsen PF, Duarte FS, Perry G, de Souza Franco E, de Sousa Maia MB.

Drugs. 2026 Jul;86(7):1103-1119. doi: 10.1007/s40265-026-02335-9. Epub 2026 May 27.

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab

Schwartz NU, Dietz CD, Lin Z, Tammewar G, Bui N, La Joie R, Wang Y, Sreekrishnan A, Suhami D, VandeVrede L, Ljubenkov PA, Rojas JC.

Neurocase. 2026 Aug;32(4):174-179. doi: 10.1080/13554794.2026.2695021. Epub 2026 Jul 2.

Standardizing care for agitation in Alzheimer's disease, results from a randomized controlled trial of an integrated care pathway versus usual care - the StaN trial

Kumar S, Burhan AM, Colman S, Chu L, Davies S, Derkach P, Elmi S, Gerretsen P, Graff-Guerrero A, Greenway K, Hussain M, Ismail Z, Kim D, Krisman L, Ma C, Moghabghab R, Mulsant BH, Pollock BG, Rej S, Rostas A, Schoer N, Streiner DL, Van Bussel L, Rajji TK; StaN Study Group.

Alzheimers Dement. 2026 Jul;22(7):e71610. doi: 10.1002/alz.71610.

Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping review

Hampel H, Nakamura Y, Bell J, Hendrix S, Derchansky M, Montezano BB, Stoeckel LE, Teipel S, Willis DR, Cummings JL, Cobb BR.

Alzheimers Dement. 2026 Aug;22(8):e71559. doi: 10.1002/alz.71559.

Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

Pascual-Lucas M, Lacosta AM, Montañés M, Canudas J, Loscos J, Monleón I, Allué JA, Sarasa L, Fandos N, Romero J, Sarasa M, Torres M, Whyms D, Terencio J, Piñol-Ripoll G, Boada M.

Alzheimers Dement. 2026 Aug;22(8):e71746. doi: 10.1002/alz.71746.

Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study

Li LL, Wang RZ, Wang Z, Hu H, Xu W, Zhu L, Sun Y, Chen KL, Chen SF, He XY, Yuan MY, Huang YY, Liu XY, Liu P, Ye QY, Wang J, Ju ZZ, Zhang W, Hu B, Guo Y, Cao XY, Li YX, Zuo CT, Cheng W, Jiang T, Tan L, Chen XC, Zhao QH, Cui M, Peng GP, Xin JW, Yu JT.

Brain. 2026 Jun 3;149(6):1973-1985. doi: 10.1093/brain/awaf427.

Cerebrospinal fluid biomarkers in Alzheimer's disease: enhancing diagnostic precision and guiding therapeutic strategies

Azadovich AP, Oralov B, Sherzod K, Kudeshova G, Feruza A, Umida B, Kambarova O, Farkhod R, Baxtiyor S, Jurabek Y, Narzikulova K, Nazirova S, Egamberdieva S.

Clin Chim Acta. 2026 Jul 15;589:121010. doi: 10.1016/j.cca.2026.121010. Epub 2026 Apr 16.

The role of YKL-40 in Alzheimer's disease pathology and drug targeting

Sha Y, Fu H, Lu K, Wang G, Wang Y.

PeerJ. 2026 Jun 8;14:e21361. doi: 10.7717/peerj.21361. eCollection 2026.

Impacts of menopausal hormone therapy on Alzheimer's disease biomarkers: A systematic review

Rodrigues AC, Valério FG, Moura CB, Da Silva AMP, Tudella GCN, Almeida SS, Gomes AC, Oliveira CEM, Apóstolos-Pereira SL, Santos DH.

J Alzheimers Dis. 2026 Aug;112(3):1143-1158. doi: 10.1177/13872877261456766. Epub 2026 Jun 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias